pagiantmetknicksfan@yahoo.com
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You have that link?
Also the link requested here too would be great
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70720218
You got that audio link for the CC?
How did you hear it if the conf call was months ago and as you stated, you just started doing your DD a few days ago. Can you provide the audio link? Eveyone should listen.
That's awesome that you have the audio
This one is likely to be in europe and as far as trials they basically need to show it safe, an blood plasma levels are maintained. Its not like a new cancer drug. Its an existing pain med where the profile is well known.
So our partner gets half and we supply the other half.
CEO was pretty clear but I guess based on one's intention you can hear what you want.
I am so friggin excited about this partnership, the Eli 216 commercial batches started a few months ago. You could hear the excitement in their voices talking about it
The patent update is amazing and basically proves the uniqueness and unexpected results of the art/tech.
Most are waiting on pending generic drug launches. I see a lot of paddy cake on the bid and ask. I am in long due to the patents pending especially the last round of arguments are pretty strong. Add in the commercial batches started, there's a lot of smoke there.
Just read the CC transcript. The CEO discusses it in pretty good detail.
The valuation on the 10k was 3.4m and that was 4-6 years ago. The FDA site will show you how many drugs have been approved. Its really not that complicated.
The CEO volunteered that information for some reason. Obviously since we just started commercial batches of an 800m abuse resistant Oxycontin, secured funding and have an asset that was valued at $3.4m back in what 2006? And has added many ANDAs/approvals since then, it is worth much more now and may come in handy.
We only need a couple million to fund the second half of the ELi154 trials, so maybe the money will be used for that.
Exciting times!!.!
I can see the approvals as they come through the FDA. Its public information and you can read all the information already posted earlier
I watch the FDA approvals and I am pretty I sure I have seen approvals for Novel over the past year
CEO is being Vague?
Please post those remarks and supporting link regarding the CEO
"One other item I'll mention is Novel Labs. You may see in our balance sheet an investment listed for Novel Laboratories. Novel
is a private pharmaceutical company located in Somerset, New Jersey. Elite owns approximately 10% of Novel from an investment
made back when Novel began operating in 2006.
It's something we've typically not said much about, but from public information, Novel currently has 15 ANDAs filed at the FDA and at least 5 approved ANDAs. Because it's a private Company, Novel does notreport earnings and revenues. But, based on their product list, which continues to grow, we believe this investment in Novel
represents a substantial and growing value."
Chris Dick - Elite Pharmaceuticals Inc - COO, President
Yes, as I said, we're approximately a 10% shareholder, obviously we aren't controlling, it's private. We're not sure when we might
monetize that, but I don't think Novel has any intention of becoming public, for example. But, as he continues to grow in value,our share in it grows in value.
And, at some point, whether he decides to do something with the company or raise additional capital or something like that,
there will be opportunities we believe down the road. We aren't really looking at a specific time any time soon for that. We're
just happy to sit there and let it grow for now.
Jerry Treppel - Elite Pharmaceuticals Inc - Chairman, CEO
Again, this is Jerry Treppel. Let me clarify a little bit. As a minority investor in a private company, under GAAP accounting rules,you can never write up the value of an asset. All you can do is write it down.So, the value, it could be worth, not saying that it is, but say it was worth twice what shows on the balance sheet, that's never going to show up on the balance sheet. It's just the way it works. And, you should know that the founder of Novel is well known.throughout the industry and, in fact, sold his previous company for an excess of $100 million to par.
This asset has been on the 10K has been listed as ~3.4m and can only be written down so the number is likely much higher than this. I believe the acquisition is from 2006 and the company is growing extremeley rapidly.
http://www.novellabs.net/
Isn't that pretty exciting!!!!!!!!
Treppel talked about Novel two conf calls ago I believe. What they have done is manage to hold on to that asset and watch it grow. Probably more then double it's value or more. I think that is part of this Socius deal too. Basically, get the financing in place so you don't have to sell off your prized asset.
Which is also what led me to think that they got the financing to show a partner they can remain solvent along the way. Having an asset is nice but as time passes the value of that asset can go up or down. Cash is Cash
If Actavis, HITK, EPIC, MIKAH, TAGI, TPN, Socius see it as not a issue and willing to put 10s of millions in business with them,guess I am ok. Plus the company addressed it on the conf call and there doesn't seem to be any concern. I am going to trust them before I trust negative message board analysis describing the situation as "hanging over their heads"
Why do you think we started up commercial batches of Eli 216, an 800m abuse resistant PH3 pending drug that has an SPA with the FDA?
Its a complete non issue. With commercial batches on an 800m abuse resistant oxycontin product started, a few million away with a partner for Eli 154 and now we have financing in place for it! Multiple drug launches anyday and we are discussing the bonds? The company addressed in the CC.
Actually it is more complicated then you understand. They are making interest payments from the debt reserve I believe which they are allowed to do. Not sure how you missed all that from the SEC filings. Again, this is a complete non issue and to become current it is about 1m-2m if they absolutely have to which they likely won't. Company has access to about 10m-20m if they had to.
Again, not worth wasting time over. Has nothing to do with operations over the next couple years. Elite didn't sound concerned at all which they really shouldn't be.
Honestly you are missing most of the data from the 10k or ommitted but whatever. Not of interest to me at all
"Hanging over their heads"?
I don't get that from
"Well, with regards to an impediment of people doing business, no, we haven't experienced any problems related to the bonds.
What we are doing with this is, and this is in our reports, we have submitted a request, which we're allowed to do to defer the
principal payments. We're allowed to request up to a five year deferral of principal payments.
We have requested three years and we made the request through our trustee and we are awaiting for a response from the
bondholders. The bondholders have to approve that request, so that's where it stands right now. The three years requested
would be -- on the fourth year we would have to repay the entire three years principal payment plus the principal payment that
is due that year. So that's the proposal that's currently out there."
Also they could come current with a small piece of the Socius or Novel $$$ but "We're allowed to request up to a five year deferral of principal payments. We have requested three years and we made the request through our trustee and we are awaiting for a response from the
bondholders."
"Hanging over their heads" Really?
Looks like we are moving forward
Here is my top 20 reasons I love what this company is doing
1. Commercial batches of Eli 216 started a few months ago. Reasons to do this are to either start PH3, or to show a partner that you can reproduce your tech on a large scale. There is expense and time involved so you only do this if you plan on moving forward. This is $800m abuse resistant Oxycontin for which they have an SPA with the FDA.
2. Socius funding for 5m. Per the last conf call the CEO stated we have a partner for half the funding of Eli 154 but their internal policies prevent them from funding the whole thing. We need a few million dollars to move forward per the last CC. We just received funding for 5-10m dollars. Eli 154 is 24 hour release Oxycontin, a $400m market.
3. Patents look to me to be very close. Go read the description of the recent discussion between Elite and the USPTO. They had a conf call to clear up what Elite needs to do to get the patents approved. It revolves around what is obvious to someone in the art. Elite has proven that not only are their results not obvious but actually counter intuitive to what an artisan would have expected. Included is documented support from experts in the field. These patents are for all opioids. The market is multi billion dollars.
4. Partnership with Mikah/Actavis – Actavis is one of the largest generic companies in the world. Mikah is acting as the middle man. Not only are we going to be doing contract work but we will be developing Mikahs top R&D projects including MIK001. I think it is for other abuse resistant or extended release formulations. This is all on Mikahs website. Mikah is Actavis.
5. Lodrane 24 and 24D should be back soon – Elite was operationally profitable on Lodrane 1 year ago. The FDA pulled 500 cold remedies last March but ECR has gone the NDA approval route which started in 2010. Their petition for stay was filed and requested to last until this quarter. While they agreed to dismiss, it does give an idea of the timeline they expected to have to get the NDA approved.
6. New instant release LodraneD is selling well per the last conference call.
7. Methadone is about to launch per last conf call.
8. Hydromorphone is pending launch, pending final go ahead from the FDA. Pre-approval inspections completed in August
9. Naltrexone is pending launch, pending final go ahead from the FDA. Pre-approval inspections completed in August
10. New ANDA is pending launch, pending final go ahead from the FDA. Pre-approval inspections completed in August
11. 8 Epic drugs will be made by Elite. The transfer of the 1st began some time ago and should be coming soon.
12. Contract manufacturing for Actavis – Isradipine alone is a 50m drug with only a couple competitors.
13. Diet product Yahoo won’t let me type for some reason
14. 100m HITK generic to be launched, Elite is making the intermediate
15. Elite owns 10% of Novel Labs. Valued at ~4m in 2006 I believe. Per the CC, and how much Novel has grown, this is probably double that.
16. Just the overall number of partners Elite has now. A bunch of companies are putting their faith in Elite on the generic and contract drug side (Actavis, Mikah, Epic, HITK, TPN, TAGI)
17. No reverse split as stated by CEO on a previous conference call and the plan is to get back on the big boards. With the abuse resistant and extended release of Opioids market being many billions of dollars, it is obvious why
18.
19. Elite is an open company. They act like a company that was traded on the big boards because they used to and plan to again. During CCs, you can ask them anything you want and you know what they are working on except for the classified drugs due to competitive reasons.
20. Other products not even described here, total of about 29 not including the others on the Mikah site that we may be making.
I definitely could
Exactly. I am curious to see that we did this deal to have the cash not only in reserve but to show we have no problem with solvency to mitigate any risk a partner would have. With the current products commercialized, Elite can run for years on the financing deal.
Remember it is much more then 5m actually. There are warrants for stock purchase at .07 which is the new floor. The deal is more like 8-11m dollars
Maybe fund Eli 216 too.....We'll see
We are spending money to produce commercial batches of Eli 216 which is of course abuse resistant Oxy, an 800m drug. We wouldn't be spending money on that unless we were moving forward in some fashion.
Here is a good link, a few years old but its just market research on abuse resistant drug market
I have had trouble with this link so if it doesn't work tell me
http://www.chiroeco.com/chiropractic/news/7641/34/us%20back%20pain%20market%20approaches%20-23%20billion%20in%202018%20-%20anticipated%20long-acting-%20abuse-resistant%20opioids%20drive%20value/?skeyword=opioids
Why do you think we started up commercial batches of an 800m PH3 pending Abuse resistant Oxycontin drug?
I think there that when the upward pressure subsides it opens the door for manipulation as explained below
Its obvious with this stock too. You buy shares with Bid A, you put them up for sale at the same price, put in another bid at Bid A-5% or so, generate negative attention, hope someone that doesn't understand how valuable the stock is get nervous and sells, rinse repeat.
Then when the stock hits which we all know it will, it runs up, they wait for the buying pressure to subside and start over again. Mostly manipulation and it is criminal at times. I hav e been reporting many thingsto the SEC who assured me they do look into these things.
Look likes a lot of safe harbor statements. You need to go read the previous CC transcript. All of that is covered in detail.
Do you guys think the 5m funding is for Eli 154? Per the conference call we need a couple million to meet our prospective partner halfway. “The CEO says if you know some people with a couple million….” Then we get 5m in funding plus more for the the warrants if Socius chooses to exercise them. Also I have wondered if maybe the funding was to show a prospective partner that Elite is not a risk for insolvency without Epic. And this way they do not have to sell Novel Labs which is worth between 4m – 8m dollars. The CEO has volunteered some interesting info about Novel at well. These guys usually are careful about what information they divulge.
And we just got 5m in available finacincing plus warrants. Per the conf call, just needed a couple million to fund the other half.
Like I said
Its obvious with this stock too. You buy shares with Bid A, you put them up for sale at the same price, put in another bid at Bid A-5% or so, generate negative attention, hope someone that doesn't understand how valuable the stock is get nervous and sells, rinse repeat.
Then when the stock hits which we all know it will, it runs up, they wait for the buying pressure to subside and start over again. Mostly manipulation and it is criminal at times. I hav e been reporting many thingsto the SEC who assured me they do look into these things.
When you have literally 30 known catalysts this will happen over and over. Some will sell miss the next run up and so on and on and on
Often penny stocks are manipulated down prior to a large scale financing or massive partnership. Since Elite has a partner for half of Eli 154 and just started commercial batches for Eli 216, a total of 1.2 billion dollar blockbuster drugs, I would say that could be it too.
Why would you start commercial batches of an 800m dollar drug?
Its just simple math. Supply and demand
Im still waiting the those links requested below
People get arrested more often then you think.
And once the volume gets low, it is incredibly easy to manipulate a stock. Yesterday 500k traded. Even if you assume only a little was manipulation or even none and just trading, then you have what 150k shares really trading hands or 250k? Thats a whopping $25k dollars. Peanuts
So I think that proves that manipulation is not only easy but likely
Often penny stocks are manipulated down prior to a large scale financing or massive partnership. Since Elite has a partner for half of Eli 154 and just started commercial batches for Eli 216, a total of 1.2 billion dollar blockbuster drugs, I would say that could be it too.
Why would you start commercial batches of an 800m dollar drug?
Can you offer any links or data to support those claims?
Its obvious with this stock too. You buy shares with Bid A, you put them up for sale at the same price, put in another bid at Bid A-5% or so, generate negative attention, hope someone that doesn't understand how valuable the stock is get nervous and sells, rinse repeat.
Then when the stock hits which we all know it will, it runs up, they wait for the buying pressure to subside and start over again. Mostly manipulation and it is criminal at times. I hav e been reporting many thingsto the SEC who assured me they do look into these things.
Or one of the other 27 products could launch
Patent could get approved
Partnership is announced
I see a coordinated bear run. No more no less.
I think you are just watching flippers looking for weak hands.
Save another 180k. Nice plus the setup for some thinking reverse merger.
I see you deleted my other post. We need a few million for the other half. I thought you read what I wrote
It took a lot for them to get approval from their Board to go forward.They just have a policy that they are not going to fully fund
a clinical trial. So, if we can come up with that money ourselves or we can find third parties to do it, they'll be happy to work
with us. So, if you know people who have a few million dollars, we'd listen to them.
Medi Amari - - Private Investor
Okay. So, they are willing to cooperate, but they are not interested to fully fund the Phase 3?
Jerry Treppel - Elite Pharmaceuticals, Inc. - Chairman of the Board, CEO
Right.They priced it out.They know what it's going to cost.They're willing to put up half the money, but not the full amount.
Medi Amari - - Private Investor
Is there any condition like if they wanted to fully invest in that, have they put any condition for Elite that probably you're think
about that?
Chris Dick - Elite Pharmaceuticals, Inc. - President, COO
Any - No, I don't think there's any conditions on us.We would be partners 50% of the cost for the clinical cost.We would fund
as a partner and they would fund half and we'd also share at some percentage down the road as well, any profits from it.
Jerry Treppel - Elite Pharmaceuticals, Inc. - Chairman of the Board, CEO
I want to emphasize that the companies that we were speaking with did a lot of work. It's serious. This was no fly-by-night
relationship with them. It's still - we still have a good relationship with them.
It took a lot for them to get approval from their Board to go forward.They just have a policy that they are not going to fully fund
a clinical trial. So, if we can come up with that money ourselves or we can find third parties to do it, they'll be happy to work
with us. So, if you know people who have a few million dollars, we'd listen to them.
Medi Amari - - Private Investor
Okay. So, they are willing to cooperate, but they are not interested to fully fund the Phase 3?
Jerry Treppel - Elite Pharmaceuticals, Inc. - Chairman of the Board, CEO
Right.They priced it out.They know what it's going to cost.They're willing to put up half the money, but not the full amount.
Hello, I'm rather new to Elite, so this question might not make much sense. But I was just looking at the 10-Q and it said the
interested party, with respect to the ELI-154 was identified that would - [on half ] the clinical trial, but that you are unable to find
a way to find the remaining cost at this time. Does that mean that, that development is at an impasse now until, well I will just
leave it at that. Is it at an impasse because you are unable to find the funding?
Chris Dick - Elite Pharmaceuticals, Inc. - President, COO
Yes, we're obviously pleased that they've done a bunch of due diligence, they believe in the opportunity, but their own model
doesn't allow them to fully fund it. So, yes, until we can identify a funding source or at some point come up with our own capital
to fund it, we are stuck.We can't go forward until we deal with that piece of the funding of the development.
Jerry Treppel - Elite Pharmaceuticals, Inc. - Chairman of the Board, CEO
This is Jerry Treppel. It's a good news, bad news situation.The good news is that our partner did a lot of work in terms of market
research, in terms of what kind of clinical trials would be necessary to get an approval in Europe, which is information we really
didn't have before, and there definitely is a market there, there's no question about that.
The question is, how do you get to the market.The way their business model works, they're require that the development costs
be shared.We obviously don't have the funds to do that. Either we come up with the funds to do that or we look for another
way to move forward.That's where it stands.
Well if that's how you read the CC transcript ok. Everyone should go read it for themselves. If you have the link, you should post it so everyone can read it.
I figured if you read the conf call transcript you would know about the partner situation, startup of commercial batches for Eli 216, pre-approval inspections etc...
Guess you are done here then. Have a good night.
Did you read the conference call transcript? pre-approval inspections for four drugs completed in August. Methadone expected any day. You should read it.
Doesn't seem that way. You have a lot of questions. Let me help you. Did you know that Elite has a European partner for Eli 154 willing to fund half the PH3 trials. ELite needs a couple million for the other half. Eli 154 is a 400m drug with compounds already approved by the FDA and I think a SPA with the FDA for this as well.
Now with the 5m dollar funding seems they can move forward if they wish or maybe the partner just need some assurances and can now fund all of the trial.